Eton Pharmaceuticals Inc (ETON) has a regulatory event to watch this week related to its investigational drug ET-600, a proprietary, patented formulation of desmopressin oral solution.
ET-600 is proposed for the treatment of central diabetes insipidius, also known as arginine vasopressin deficiency, with the FDA decision expected on February 25, 2026.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.